期刊
JOURNAL OF DIABETES AND ITS COMPLICATIONS
卷 28, 期 3, 页码 393-398出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2013.12.009
关键词
Exenatide; ITCA 650; Type 2 diabetes
资金
- Intarcia Therapeutics Inc., Hayward, California
Aims: Evaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes treated for up to 48 weeks. Methods: This was a 24-week extension to a randomized, 24-week, open-label, phase 2 study in subjects with type 2 diabetes inadequately controlled with metformin. Subjects received ITCA 650 mg (20, 40, 60 or 80 mu g/day). Mean changes for HbA1c, weight, and fasting plasma glucose (FPG) were evaluated. Results: Mean changes in HbA1c from baseline to week 48 ranged from -0.85% to -1.51%. At week 48, >= 64% of subjects with an HbA1c <= 7% at week 24 maintained an HbA1c <= 7%. The incidence of adverse events (AEs) was dose-related and ranged from 13.3% with 20 mu g/day to 37.5% with 80 mu g/day. Most AEs were mild and transient; the incidence of nausea declined from 12.9% to 9.5% over the 24-week extension. One subject on ITCA 650 80 mu g/day experienced mild intermittent vomiting. Three (3.5%) subjects experienced severe AEs, but none were considered related to study drug. Conclusion: Significant changes in HbA1c, body weight, and FPG attained with ITCA 650 were maintained to 48 weeks. The incidence of AEs was lower in the 24-week extension than in the initial 24-week treatment phase. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据